TABLE 6.

Summary of fluconazole prophylaxis study in ELBW infants^a

Characteristic	Results for:		P
	Fluconazole patients (n = 50)	Placebo patients (n = 50)
No. (%) of patients with fungal infectionb
Blood, urine, or cerebrospinal fluid infection	0 (0)	10 (20)	0.008
Bloodstream infection	0 (0)	8 (16)	0.007
No. (%) of patients with fungal colonization
One or more sites	11 (22)	30 (60)	0.002
Two or more sites	9 (18)	26 (52)	0.003
Skin	10 (20)	24 (48)	0.008
Gastrointestinal tract	9 (18)	27 (54)	0.003
Respiratory tract	1 (2)	21 (42)	0.002
Resistance (MIC50) (μg/ml)
First 6 mo of study	≤2.0	≤1.0
Last 6 mo of study	≤2.0	≤1.0
Patient safety (liver function tests, mean ± SD)
Aspartate aminotransferase (IU/liter)	27 ± 13	29 ± 16	0.67
Alanine aminotransferase (IU/liter)	21 ± 16	21 ± 19	0.85
Direct bilirubin (mg/dl)	0.6 ± 1.4	1.0 ± 1.8	0.34
Alkaline phosphatase (IU/liter)	305 ± 125	318 ± 182	0.70
No. (%) patients who died	4 (8)	10 (20)	0.22

^aData from reference 246.

^bGrowth of fungus in culture for a patient with symptoms of infection.